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 ABSTRACT 
 Objectives  To investigate the effect of group cognitive 
behavioural therapy (CBT) for fatigue self-management, 
compared with groups receiving fatigue information 
alone, on fatigue impact among people with rheumatoid 
arthritis (RA). 
 Methods  Two-arm, parallel randomised controlled 
trial in adults with RA, fatigue ≥6/10 (Visual Analogue 
Scale (VAS) 0–10, high bad) and no recent change in 
RA medication. Group CBT for fatigue self-management 
comprised six (weekly) 2 h sessions, and consolidation 
session (week 14). Control participants received fatigue 
self-management information in a 1 h didactic group 
session. Primary outcome at 18 weeks was the impact of 
fatigue measured using two methods (Multi-dimensional 
Assessment of Fatigue (MAF) 0–50; VAS 0–10), analysed 
using intention-to-treat analysis of covariance with 
multivariable regression models. 
 Results  Of 168 participants randomised, 41 withdrew 
before entry and 127 participated. There were no major 
baseline differences between the 65 CBT and 62 control 
participants. At 18 weeks CBT participants reported 
better scores than control participants for fatigue 
impact: MAF 28.99 versus 23.99 (adjusted difference 
−5.48, 95% CI −9.50 to −1.46, p=0.008); VAS 5.99 
versus 4.26 (adjusted difference −1.95, 95% CI −2.99 
to −0.90, p<0.001). Standardised effect sizes for 
fatigue impact were MAF 0.59 (95% CI 0.15 to 1.03) 
and VAS 0.77 (95% CI 0.33 to 1.21), both in favour of 
CBT. Secondary outcomes of perceived fatigue severity, 
coping, disability, depression, helplessness, self-effi cacy 
and sleep were also better in CBT participants. 
 Conclusions  Group CBT for fatigue self-management 
in RA improves fatigue impact, coping and perceived 
severity, and well-being. 
 Trial registration: ISRCTN 32195100 
 INTRODUCTION 
 Rheumatoid arthritis (RA) is a systemic, infl amma-
tory condition causing synovitis in multiple joints, 
pain, joint destruction and disability. 1 Treatment 
comprises medication to control infl ammation, 
and multidisciplinary team interventions to reduce 
symptoms and maximise self-management. 2  3 
Patients highlight fatigue as a major concern, 4 
as important as pain, 5 – 8 overwhelming, unman-
ageable and ignored by clinicians. 9 – 11 Signifi cant 
fatigue occurs in up to 70% of patients with RA, 
can be as severe as chronic fatigue syndrome, pre-
dicts quality of life and is as hard to cope with as 
pain. 12 – 16 The highlighting of fatigue as an unmet 
concern by patients with RA led to international 
consensus that fatigue must now be evaluated in 
all RA clinical trials. 17 
 RA pharmacological treatments reduce but do 
not resolve fatigue, and associations between RA 
fatigue and measures of infl ammation, clinical 
or psychological health are only moderate. 18  19 
Fatigue is likely to have complex, multicausal path-
ways comprising varying combinations of clinical 
(infl ammation, pain, disability) and psychosocial 
factors (mood, beliefs, coping, behaviours), 13  19 – 23 
implying that effective fatigue self-management 
strategies are critical. Enabling self-management for 
people with long-term conditions is a government 
target 24 and RA guidelines recommend support 
for fatigue. 2  3 Many rheumatology teams provide 
general self-management education, 25 but with 
no systematic review of RA fatigue interventions, 
 clinicians are uncertain how to help. 26 
 Multiple sclerosis fatigue was improved by a 
fatigue self-management programme of individual 
cognitive behavioural therapy (CBT). 27 CBT deals 
with links between thoughts and feelings that may 
drive behaviours, and uses cognitive restructuring 
to help patients make behavioural changes. 28 For 
example, thoughts that tasks must be done per-
fectly, with feelings of failure if they are not, may 
drive excessive work patterns, leading to fatigue. In 
CBT, core self-management skills of problem-solv-
ing and goal-setting, and peer role models (social 
cognition theory, SCT) enhance self-effi cacy, or 
confi dence that you can do something to make a 
difference. 29 A systematic review of general self-
management programmes in rheumatic diseases 
recommends that they incorporate SCT or CBT. 25 
A randomised controlled trial (RCT) of 16 h group 
(SCT) education for patients and partners, covered 
comprehensive topics, but not fatigue specifi cally. 30 
Perceived fatigue improved in patients attending 
alone, but increased in those accompanied by part-
ners. There were no other clinical or psychological 
benefi ts and the study was restricted to patients 
with partners. An RCT of 22 h group (SCT) CBT 
covered comprehensive topics, fatigue and prac-
tice (eg, exercises, tai chi). 31 Fatigue severity, pain, 
function and mood improved, but the study was 
restricted to patients with mild/moderate disabil-
ity. In an RCT of 11 h individual CBT, participants 
selected two of four modules, with fatigue as one 
option. Fatigue and depression improved but no 
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other clinical or psychological outcomes, and the study was 
restricted to people with early RA in psychological distress. 32 
 Given that RA fatigue is not strongly associated with dis-
ability, disease duration or distress 19 and occurs in at least 70% 
of patients, self-management interventions should target the 
broad RA population. Furthermore, as RA fatigue affects qual-
ity of life, 9 – 11  14  15 an intervention that changes fatigue impact 
might be expected to change wider well-being. The aim of 
this study, therefore, was to test, in an inclusive cohort, the 
null hypothesis that there would be no difference in change in 
fatigue impact between people with RA participating in a group 
CBT fatigue self-management programme and groups receiving 
fatigue information alone. Secondary outcomes were perceived 
fatigue severity, coping and clinical and psychological well-
being. People can be at different stages of readiness to change 
 behaviour 33 therefore stage-of-change data were collected for 
exploratory analysis. 
 METHODS 
 Trial design 
 This was a two-centre controlled trial of group CBT for fatigue 
self-management versus group information (usual care), with 
balanced randomisation (1:1), conducted in the UK. 
 Participants 
 Inclusion criteria were adults with confi rmed RA 34 scoring ≥6 
for fatigue during the past week (Visual Analogue Scale (VAS), 
no fatigue–extreme fatigue, 0–10). Exclusion criteria were 
change in disease-modifying drugs or biological agents within 
the preceding 24 weeks (glucocorticoids 6 weeks). Participants 
were recruited from rheumatology departments in two teaching 
hospitals in Bristol, UK, approached in person (consecutive 
patients attending clinic) or by letter (via departmental RA data-
bases, randomly mailed in batches of 40). Ethics approval was 
obtained (North Somerset and South Bristol research ethics 
committee, P6/Q2006/149), and the study registered (ISRCTN 
32195100). Information sheets provided neutral information on 
the trial arms, and patients gave written informed consent. 
 Interventions 
 The study team developed the CBT intervention from their clini-
cal chronic pain and chronic fatigue syndrome self-management 
programmes (NA, BK), incorporating experiences of RA fatigue 
from clinics (SH), self-management programmes (AH, DP) 
and patients (patient research partner KK). 35 The programme 
was piloted, refi ned, then co-delivered by clinical psycholo-
gist NA and specialist occupational therapist BK, in 6 × 2 h ses-
sions (weeks 1–6), with a 1 h consolidation session (week 14). 
Topics likely to improve fatigue self-management were included 
( table 1 ). Thoughts, feelings and behaviours related to fatigue 
were addressed using Socratic (refl ective) questioning and guided 
discovery to enable patients to work out links themselves. 36 
Problem-solving, goal-setting, self-monitoring of activity/rest 
and energy management, aimed to help patients turn cognitive 
and behavioural changes into improved well-being. Goal-setting 
occupied the second hour of sessions, each clinician taking half 
the group to help patients set and review personal cognitive or 
behavioural goals. Programme homogeneity across groups was 
maintained through standardised topics, tools, metaphors and 
handouts, delivered by the same clinicians. 
 The information-only control arm comprised a 1 h didactic 
group session delivered by a rheumatology specialist nurse (DP), 
 Table 1 Cognitive behavioural therapy intervention topics for each session plus supporting materials 
 Week  1st Hour  Support materials  2nd Hour 
1 a) Course purpose and expectations—Why are we here?
b) Establish ground rules
  Commitment, confi dentiality, homework
c) Validate your fatigue—share and discuss
 Fatigue experiences (differentiate from fl are)
  Self-management strategies and struggles to change
H: Arthritis Research UK booklets
H: Setting our course (groups’ ideas)
Energy management
 Boom and bust behaviour
  Rewards/pitfalls of boom and bust
 Prioritise, balance, pace, plan
 Barriers to pacing, choices
H: Achieving a balance
H: Activity cycling
T: Energy management diaries
2 a) What are your priorities for change in your life?
 What are your drainers and energisers?
b) Self-sabotage in the course—How might you do that?
T: Wheel of life (priority areas)
H: Best ways of self-sabotage
Goal setting (in groups of 3–4)
 Individual short-/long-term goals
 Use peer group for ideas
 Contracting
3 Sleep and rest
 How much do we need? Quality vs quantity
 Sleep hygiene strategies for individual patients
H: Getting a better night’s sleep
T: Sleep diary (if needed)
Goal-setting review, new goals
4 Stress and relaxation
 Personal stressors, physiological reactions to stress
 Relaxation rationale and techniques
H: Effects of stress
H: Relaxation practice guide
T: Relaxation CD
Goal-setting review, new goals
5 Assertiveness
 Passive, manipulative, assertive? Which are you?
 Other people’s reactions to these?
 Communicating your needs
M: Cartoon examples
H: Saying ‘No’
Goal-setting review, new goals
6 Reviewing our self-help toolkit, course consolidation
  What have you learnt? Review each topic
Dealing with setbacks—what might you do?
 Negative self-talk, automatic thoughts and rumination
M: Islands:
 Desert island now=passive
 Mainland=unrealistic 100% health
  Adaptive coping island=realistic (good life despite 
rheumatoid arthritis)
M: Fatigue pit: falling in, digging out
H: The pit and tools to dig yourself out
H: Coping with setbacks
Goal-setting review, new goals
7 Review past 8 weeks and all topics
 How did you get on?
 How did you/will you deal with setbacks?
 Goal follow-up
  
 H, handouts; M, metaphor; T, tools. 
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based on the Arthritis Research UK leafl ets ‘Fatigue and RA’ and 
fatigue excerpts from ‘Looking after your joints,’ freely avail-
able in rheumatology clinics. The session covered fatigue symp-
toms, consequences, causes and self-management suggestions 
(pacing, planning, stress, sleep). Both arms received the Arthritis 
Research UK leafl ets. 
 Outcomes 
 Fatigue impact at 18 weeks was the primary outcome, assessed 
by the Multi-Dimensional Assessment of Fatigue scale (MAF, 
0–50) 37 and a VAS (no impact–very great impact, 0–10). 
Secondary outcomes were perceived fatigue severity (no fatigue–
extreme fatigue), coping (very poorly–very well), pain (no pain–
pain as bad as it could be) and perceived disease activity (doing 
very well–very badly) measured using VAS (0–10). Disability 
was measured by the Health Assessment Questionnaire (HAQ, 
0–3) 38 and Personal Impact HAQ (0–9). 39 Wider outcomes were 
measured by the RA Quality-of-Life scale (0–30), 40 Hospital 
Anxiety and Depression Scale (0–21), 41 Arthritis Helplessness 
Index (5–30), 42 RA Self-Effi cacy scale (RASE, 28–140) 43 and a 
sleep quality question (very good, fairly good, fairly bad, very 
bad), 44 recoded as a binary variable as numbers were insuffi cient 
for analysis. Baseline readiness to make cognitive or behavioural 
changes was measured using the Arthritis Stages of Change 
(ASOC) subscales (8–40). 33 Higher scores always refl ect worse 
health status, except fatigue coping VAS, RASE and ASOC 
where they refl ect stronger beliefs. Outcomes were measured at 
0, 6, 10 and 18 weeks. 
 Sample size 
 Forty-four patients in each arm were needed to show a differ-
ence of 7 MAF points in fatigue impact between trial arms, with 
90% power and estimated SD 10 points (two-tailed signifi cance 
0.05) (based on unpublished data). No minimal clinically impor-
tant difference has been published for MAF in RA, but is 5 in 
lupus. 45 
 Randomisation 
 The intervention and control sessions were delivered to groups, 
therefore whenever 12–16 participants had been recruited, 
project managers (AC, CA) emailed participant codes to epi-
demiologist JP who performed randomisation off-site, using 
computer-generated random numbers. Allocation was 1:1 but 
in the event of an unequal number, the CBT arm received the 
additional patient. To reduce hospital visits, baseline data were 
collected immediately before the fi rst CBT or control session 
(after randomisation). 
 Blinding 
 Delivery methods and the need to encourage participants to 
make cognitive and behavioural changes, rendered blinding of 
participants and clinicians impossible. However, all assessments 
were self-reports using validated measures and analysed blind 
to allocation (JP). 
 Statistical methods 
 Baseline characteristics were described using means and SDs 
or numbers and percentages for continuous and categorical 
variables, respectively. The primary intention-to-treat analysis 
involved between-arm comparisons for fatigue impact outcome 
scores (MAF, VAS Fatigue Impact) at 18 weeks, adjusted for 
respective baseline values. These analyses of covariance were 
implemented using multivariable linear regression  models. 
Standardised effect sizes for the primary outcome were cal-
culated (adjusted mean difference divided by pooled baseline 
SD), with >0.5 considered a large effect. Secondary sensitivity 
analyses of primary outcomes were conducted by (1) additional 
adjustment for any variables displaying imbalance at baseline; 
(2) fi tting multilevel mixed-effects models to investigate any 
clustering effect from delivery in groups and (3) multiple impu-
tation (MI) techniques to investigate the impact of missing data, 
based on 20 imputed datasets, with baseline fatigue severity, 
impact, pain and perceived disease activity added to the impu-
tation model as variables predictive of missingness. 46 Secondary 
outcomes were then analysed in the same way. Further analy-
ses using repeated-measures mixed-effects analysis of covari-
ance models examined the effect of interventions over time by 
including up to three follow-up scores per participant for each 
primary outcome (MAF, Impact VAS), adjusting for baseline 
scores. Convergence/divergence between trial arms over time 
was investigated by including appropriate interaction terms in 
the model, and the clustering effect of group delivery was again 
investigated by including group identifi er as a third level. All 
analyses were conducted using Stata version 11. 
 RESULTS 
 Of 1342 individuals invited to participate, 19% (n=254) 
responded and were eligible, and of these 66% (n=168) provided 
verbal consent to participate and were randomised ( fi gure 1 ). Of 
the 168 randomised, 24% (n=41) withdrew from the trial before 
providing written consent and baseline data. Therefore a total 
of 127 participants were allocated to either CBT (n=65) or the 
control group (n=62). They were contacted for follow-up data 
at 6, 10 and 18 weeks after their intervention started, with 74 
and 76 (58%, 60%) completing all three follow-ups for MAF 
and VAS, respectively. The 41 who withdrew had similar char-
acteristics to the 127 who participated for gender (85.4% vs 
76.2% female), age (57.6 years vs 59.2 years) and disease dura-
tion (14.8 years vs 14.5 years). At baseline, participants reported 
high levels of fatigue impact and severity, and limited ability to 
cope with fatigue ( table 2 ). In contrast they reported lower lev-
els of disease activity and pain. Mean scores for contemplating 
changing behaviour were higher than pre-contemplation. There 
were similar characteristics across arms, apart from sleep qual-
ity, which appeared poorer in CBT participants. Twenty CBT 
and 20 control subjects (35.4%) had attended a general RA self-
management programme an average 4.0 years earlier. 
 Thirteen control groups were conducted, comprising 2–8 par-
ticipants (mean 5), with 11 CBT groups, comprising 4–9 partici-
pants (mean 6). Of the 65 CBT participants, 66.2% (43) attended 
most sessions (30 attended all seven, 13 attended six); 18.5% (12) 
attended three to fi ve sessions, largely citing illness if a reason 
was given for intermittent non-attendance; 15.4% (10) withdrew 
after less than three sessions, and where offered, reasons were 
largely poor health, or lack of interest (2). This was a pragmatic 
trial offered in addition to usual care, which included medication 
change. Forty-four (34.6%) participants had changes to major 
RA medication during the trial, which was similar between arms 
(24 (36.9%) CBT vs 20 (32.3%) control); 20 (15.7%) were receiv-
ing or started antidepressant drugs (9 vs 11) and 33.1% physio-
therapy or occupational therapy (20 vs 22). 
 Primary outcome 
 Primary outcome data at 18 weeks were obtained for 65% (MAF) 
and 67% (VAS fatigue impact) of the 127 participants. There 
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was strong evidence of a benefi cial effect of CBT at 18 weeks 
with signifi cant differences between trial arms for fatigue impact 
( table 3 ). The standardised effect size for MAF was 0.59 (95% 
CI 0.15 to 1.03) and 0.77 for fatigue impact VAS (95% CI 0.33 to 
1.21) in favour of the CBT intervention. Neither additional adjust-
ment for variables possibly imbalanced at baseline (age, gender, 
sleep, disease duration and readiness to change), nor inclusion of 
‘group’ using multilevel models made any material difference to 
the primary outcomes, therefore results from the simple analyses 
of covariance are presented. Analyses based on MI of missing 
data resulted in slight attenuation of effects and improvements 
in precision, but made no material difference to the conclusions 
drawn from primary analyses. Adjusted treatment differences for 
MI models were MAF −4.13 (95% CI −7.86 to −0.40, p=0.03) and 
VAS −1.47 (95% CI −2.39 to −0.55, p=0.002). 
 Secondary outcomes 
 There was evidence of a benefi cial effect of the intervention on 
fatigue coping and perceived severity ( table 4 ). In addition, there 
were benefi cial effects on disability, depression, helplessness, 
self-effi cacy and sleep. Again, additional adjustment for age, 
gender, sleep, disease duration, readiness to change or group 
made no difference. There was no evidence of an intervention 
effect on perceived disease activity, pain, anxiety, quality of life 
or disability impact. 
 Effects over time 
 The median number of follow-ups for each person was four, 
with this being true for 60% (n=76) of individuals. Repeated-
measures mixed-effects analyses showed no interaction effects 
with time, for fatigue impact (MAF p=0.68 for interaction terms; 
VAS impact p=0.16) ( fi gure 2 ). Main effects (average difference 
across all time points) for CBT versus control were −4.57 for 
MAF (95% CI −6.57 to −2.57, p<0.001) and −1.47 (95% CI 
−2.01 to −0.93, p<0.001) for VAS impact. By the end of the main 
6 week CBT programme there appeared to be clinical differences 
emerging between the arms for fatigue and clinical variables, 
maintained at 10 weeks (online supplementary table 5). These 
 Figure 1   Flow chart of participants. CBT,  cognitive behavioural therapy; MAF, MAF, Multi-dimensional Assessment of Fatigue (scale); VAS, Visual 
Analogue Scale. 
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time points were not tested for statistical signifi cance (potential 
multiple testing), and as the fi nal booster CBT session occurred 
at 14 weeks, the primary end point was 18 weeks. 
 DISCUSSION 
 These results indicate an effect of group CBT for fatigue self-
management on fatigue impact, coping and perceived severity 
and a range of clinical and psychological variables. The minimal 
clinically important difference for VAS fatigue severity is 1, 47 
and fatigue impact probably lies within a similar range, implying 
this mean change (2.03) is clinically relevant. Pain and perceived 
disease activity were not changed, but their association with 
fatigue remains unclear 19 and although fatigued, participants did 
not report high baseline levels of either. 
 The study was limited by withdrawal of participants before 
baseline, many citing unsuitable session dates or fl are/illness 
(none reported being too tired). Baseline data were collected 
after randomisation, which might potentially have biased 
responses, but the data showed that groups were well matched. 
Participants had low baseline scores for pre-contemplating 
change, suggesting others who are in pre-contemplation might 
have been less likely to agree to a self-management programme. 
However, adjusting for readiness to change did not alter the fi nd-
ings. Readiness to change was only measured at baseline, there-
fore we could not evaluate whether people progressed through 
stages during the intervention, although related concepts of self-
effi cacy and helplessness improved. Some participants did not 
complete all follow-ups but the majority of CBT participants 
attended all or most sessions, suggesting commitment to the 
intervention. The impact of missing data, as considered using 
MIs, is unknown. These may not be missing at random, poten-
tially giving slightly infl ated treatment effects. It was not possi-
ble to blind participants and staff, but self-report measures were 
analysed blind to arm allocation. There was no control for the 
social effects of six group CBT sessions, as it was considered six 
control sessions giving fatigue information alone would mean 
 Table 3  Primary outcome scores for fatigue impact at 18 weeks 
 
 Control  CBT  Adjusted difference * 
(95% CI)  p Value  Baseline  18 weeks  n  Baseline  18 weeks  n 
Fatigue Impact, MAF (0–50) 30.46 (9.25) 28.99 (11.31) 43 30.99 (9.33) 23.99 (10.86) 40 −5.48 (−9.50 to −1.46) 0.008
Fatigue Impact, VAS (0–10) 5.9 (2.71) 5.99 (2.72) 44 6.29 (2.38) 4.26 (2.78) 41 −1.95 (−2.99 to −0.90) <0.001
 Except where indicated otherwise, all values are expressed as mean (SD). Except where indicated otherwise, high scores refl ect worse health. 
 * Adjusted for baseline score. 
 CBT, cognitive behavioural therapy; MAF, Multi-dimensional Assessment of Fatigue (scale); VAS, Visual Analogue Scale. 
 Table 2  Baseline summary statistics split by trial arm 
 Variable 
 Trial arm 
 Total (n=126)  Control (n=62)  CBT (n=65) 
Gender: female, n (%) 44 (71) 49 (75.4) 93 (73.2)
Age (years) 58.25 (12.0) 61.1 (10.5) 59.2 (11.3)
Disease duration (years) 14.6 (10.6) 14.2 (11.6) 14.0 (11.1)
Fatigue measures
 Impact, MAF (0−50) 30.5 (9.3) 31.0 (9.3) 30.7 (9.3)
 Impact, VAS (0–10) 5.9 (2.7) 6.3 (2.4) 6.1 (2.5)
 Severity, VAS (0–10) 6.1 (2.5) 6.5 (2.3) 6.3 (2.4)
 Coping, VAS (0–10) * 6.0 (2.3) 5.3 (2.4) 5.7 (2.4)
Pain, VAS (0–10) 4.8 (2.4) 4.6 (2.5) 4.0 (2.5)
Disease activity, VAS (0–10) 4.1 (2.5) 3.8 (2.1) 4.0 (2.3)
Disability, HAQ (0–10) 1.6 (0.7) 1.5 (0.6) 1.6 (0.7)
Impact disability, PIHAQ (0–9) 3.8 (1.9) 3.8 (1.7) 3.8 (1.8)
Quality of life, RAQoL (0–30) 17.6 (6.5) 15.6 (6.6) 16.6 (6.6)
Anxiety, HADS (0–21) 9.1 (4.8) 8.3 (4.6) 8.7 (4.7)
Depression, HADS (0–21) 7.3 (3.9) 6.9 (3.4) 7.1 (3.7)
Helplessness, AHI (5–30) 18.8 (5.0) 17.0 (4.6) 17.9 (4.8)
Self-effi cacy, RASE (28–140) * 103.5 (16.5) 106.1 (14.1) 104.8 (15.3)
Readiness to change, ASOC (8–40) * 
 Pre-contemplation 18.1 (6.2) 18.1 (4.7) 18.1 (5.4)
 Contemplation 28.9 (6.8) 29.0 (5.0) 29.0 (6.0)
 Action 26.7 (7.1) 28.3 (4.3) 27.5 (5.8)
 Maintenance 25.5 (6.2) 25.9 (5.1) 25.7 (5.7)
Fatigue change past week, MAF item 16, n (%)
 Decreased 3 (4.9) 2 (3.1) 5 (4.0)
 Same 25 (41.0) 24 (37.5) 49 (39.2)
 Up and down 30 (49.2) 31 (48.4) 61 (48.8)
 Increased 3 (4.9) 7 (10.9) 10 (8)
Sleep quality: good, n (%) 27 (45) 23 (37.7) 50 (41.3)
 Except where indicated otherwise, all values are expressed as mean (SD). Except where indicated otherwise, high scores refl ect 
worse health. 
 * High scores refl ect stronger beliefs. 
 AHI, Arthritis Helplessness Index; ASOC, Arthritis Stages of Change; MAF, Multi-dimensional Assessment of Fatigue (scale); HADS, 
Hospital Anxiety and Depression Scale; HAQ, Health Assessment Questionnaire; PIHAQ, Personal Impact HAQ; RAQoL, Rheumatoid 
Arthritis Quality of Life (instrument); RASE, Rheumatoid Arthritis Self-Effi cacy scale; VAS, Visual Analogue Scale.  
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high attrition. However, studies that have controlled for social 
effects by matching numbers of group sessions, still show CBT 
to be superior. 31 Many participants had medication changes for 
RA infl ammation, in this pragmatic trial refl ecting usual clinical 
practice. However, these changes were not obviously different 
between arms, and association between infl ammation and RA 
fatigue remains unclear. 19 Future research should evaluate the 
longer-term effects of CBT for RA fatigue, cost-effectiveness for 
this CBT programme versus longer durations 30  31 and individual 
versus group CBT. 32  48 
 Other self-management interventions based on CBT or SCT 
have improved fatigue but were tested in restricted RA popu-
lations, 30 – 32 while this CBT intervention improved fatigue 
in a broad range of patients with RA experiencing fatigue. 
Furthermore, fi ndings were not altered when adjusted for age, 
disease duration, gender or baseline stage of change, suggesting 
a widely applicable intervention. 
 This CBT intervention focused entirely on thoughts, feel-
ings, behaviours, personal interactions, stressors and issues 
likely to have an impact on fatigue, yet demonstrated a wide 
range of additional clinical and psychological benefi ts. Such 
wider benefi ts were also seen in a general CBT/SCT interven-
tion that dealt with fatigue 31 but not in two other CBT/SCT 
interventions. 30  32 All four interventions have similar theoreti-
cal underpinnings, therefore possible reasons for differences 
in wider outcomes may lie in the populations or outcome 
measures selected, or the social enhancement of group CBT 
versus individual CBT or with a partner. 30  32 This 13 h group 
CBT intervention concentrating on fatigue, produced wide-
ranging clinical and psychological benefi ts similar to those of 
a broader 22 h group CBT intervention with a range of topics 
(including fatigue) and practice sessions. 31 Concentrating on 
improving fatigue self-management may lead to improvement 
in well-being if those broader variables are driven by fatigue. 
Alternatively, the skills that patients develop to manage fatigue 
may also be useful in managing mood and thus improve well-
being. A direct comparison of fatigue-focused versus broader 
self-management programmes might elucidate potential 
mechanisms. 
 During the stressors and communication sessions, patients 
reported that personal interactions with family can be both 
supportive and stressful in relation to fatigue. Personal 
 interactions play a role in RA fatigue 49 and attending groups 
with a partner increased fatigue. 30 CBT is more commonly 
delivered to  individuals, exploring their unique links between 
thoughts, feelings and behaviours, 27  32 but this study showed 
that group CBT can pursue individual goal-setting in subgroups, 
and still improve fatigue and well-being. In this intervention the 
size and composition of groups, and interactions between par-
ticipants varied, yet adjusting for group made no difference to 
the fi ndings. 
 This study lends support to the theory that complex inter-
actions between disease, personal context, cognitions and 
behaviours drive fatigue (and thus its impact), 23 as a range of 
health benefi ts resulted from group CBT for RA fatigue, deliv-
ered by CB therapists. In clinical practice, interventions must 
be delivered pragmatically and effi ciently. Embedding such an 
intervention within the clinical rheumatology team is essential, 
given that trained CB therapists are not readily available to most 
teams, and improving access to psychological therapies is rec-
ommended. 50 A developmental project is therefore exploring 
whether, after brief training in CB approaches, the usual clini-
cal team could lead this intervention using a detailed manual 
( leading to a clinical trial). 
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 Table 4  Secondary outcomes at 18 weeks 
 Variable  Control (18 weeks)  Intervention (18 weeks)  Adjusted difference * (95% CI)  p Value 
Fatigue measures
 Severity, VAS (0–10) 6.22 (2.63) 4.82 (2.54) −1.56 (−2.59 to −0.54) 0.003
 Coping, VAS (0–10) † 5.98 (2.54) 7.19 (1.91) 1.33 (0.37 to 2.30) 0.007
Pain, VAS (0–10) 4.86 (2.81) 4.06 (2.44) −0.81 (−1.84 to 0.22) 0.12
Disease activity, VAS (0–10) 3.99 (2.34) 3.17 (2.25) −0.62 (−1.48 to 0.24) 0.16
Disability, HAQ (0–10) 1.75 (0.68) 1.30 (0.61) −0.19 (−0.36 to −0.02) 0.031
Impact disability, PIHAQ (0–9) 3.71 (1.63) 2.97 (1.53) −0.22 (−0.72 to 0.29) 0.4
Quality of life, RAQoL (0–30) 14.80 (9.97) 11.15 (6.65) −0.48 (−3.40 to 2.45) 0.75
Anxiety, HADS (0–21) 7.59 (4.74) 5.32 (4.61) −0.78 (−2.03 to 0.47) 0.22
Depression, HADS (0–21) 7.55 (4.51) 4.88 (3.66) −1.98 (−3.20 to −0.75) 0.002
Helplessness, AHI (5–30) 18.27 (4.99) 13.78 (4.23) −3.13 (−4.73 to −1.53) <0.001
Self-effi cacy, RASE (28–140) † 104.16 (12.66) 112.12 (21.33) 6.74 (0.24 to 13.25) 0.042
    Adjusted OR * (95% CI)  
Sleep quality: good, n (%) 25 (56.82) 31 (75.61) 0.34 (0.12 to 0.95) 0.04
 Except where indicated otherwise, all values are expressed as mean (SD). Except where indicated otherwise, high scores refl ect 
worse health. 
 * Adjusted for baseline score. 
 † High scores refl ect stronger beliefs. 
AHI, Arthritis Helplessness Index; HADS, Hospital Anxiety and Depression Scale; HAQ, Health Assessment Questionnaire; 
PIHAQ, Personal Impact HAQ; RAQoL, Rheumatoid Arthritis Quality of Life (instrument); RASE, Rheumatoid Arthritis Self-Effi cacy 
scale; VAS, Visual Analogue Scale.
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